Revised hepatitis B trial in Guinea-Bissau reopens a fraught debate over risk, consent, and infant protection
The proposed hepatitis B vaccine trial in Guinea-Bissau has returned in altered form after months of dispute over whether the study design crossed an ethical line. Danish researchers behind the project are now defending a revised protocol after ethics review bodies in Denmark and Guinea-Bissau approved changes to the original plan, a shift that gives the study a renewed path forward but does not erase the controversy that surrounded it.
The trial sat at the center of an unusually sharp international backlash. Guinea-Bissau’s government, the Africa Centres for Disease Control and Prevention, and the World Health Organization all voiced objections or concerns earlier this year, reflecting the intensity of the disagreement over whether the study’s design was acceptable in a setting where infant hepatitis B prevention has immediate clinical consequences.
One sentence in the original design drove much of the criticism.
Half of the 14,000 children would have received hepatitis B vaccine at birth alongside BCG and oral polio vaccine, while the other half would instead receive hepatitis B vaccination at 6 weeks of age, which is the current standard in Guinea-Bissau. Investigators planned to observe health differences between the two cohorts. The ethical objection was obvious and severe: one arm would spend the earliest weeks of life with a higher vulnerability to hepatitis B infection than the other, even if both groups eventually received protection.
The clinical logic behind early hepatitis B vaccination is straightforward. Hepatitis B transmission in infancy can lead to chronic infection, and chronic infection acquired early in life carries long-term liver risk. From a public health standpoint, the birth dose is intended to close the window between delivery and the first routine infant vaccine visit, when exposure can still occur and immune protection has not yet been established. A study that deliberately shifts some children away from that protection to later infancy therefore raises a hard question: how much uncertainty about downstream health is acceptable when the intervention itself is already part of standard prevention?
That question became even more charged because critics described the trial as “neocolonialist,” a label that captured concerns about power, geography, and who bears research risk when studies are conducted in lower-income settings. Those concerns were sharpened by the fact that the project had been backed by US funding and then publicly associated with US health secretary Robert F Kennedy Jr, an antivaccine activist who was pushing changes to childhood immunisation policy in the United States. In that context, a trial designed to explore possible negative consequences of a vaccine could not be separated from the politics around vaccine skepticism.
The revised protocol changes one of the core elements that made the original design so contentious. Mothers recruited to the study will now be offered hepatitis B vaccination, although the article excerpt does not spell out all of the remaining procedural details. Even so, the shift is meaningful. Offering the vaccine to mothers moves the study away from a design that appeared to withhold a protective intervention from a portion of infants and toward one that appears more willing to address maternal protection at enrollment.
The ethical stakes in this type of study are not abstract. Birth vaccination strategies are built around timing because the first weeks of life are biologically fragile. In hepatitis B prevention, the earlier vaccine is given, the sooner the infant can begin building protection against infection at a point when exposure may occur through household contact or during the birth process itself. Delaying the vaccine to 6 weeks may be routine in one national program, but comparing that schedule with birth dosing in a randomized setting means the trial must justify why the added delay is scientifically necessary and how any incremental risk will be minimized.
The altered approval pathway suggests that ethics committees in both countries saw enough change in the protocol to reopen the study. Still, approval does not settle the debate. It simply means the trial has moved from being viewed as unacceptable in its original form to being considered potentially permissible under a new design. For clinicians and researchers, that shift will invite close scrutiny of how consent is handled, how infant and maternal protection are balanced, and whether the study asks a question that can be answered without exposing participants to avoidable harm.
This case also exposes a broader fault line in global health research. When a trial examines an intervention that is already widely used, the burden on investigators rises sharply. The question is no longer whether a vaccine works in principle; it is whether a specific schedule, setting, or implementation strategy creates measurable differences that justify the ethical cost of randomization. In infant vaccination research, even small changes in timing can take on outsized importance because the outcome space includes infection, immunity, and the irreversible consequences of early-life exposure.
For now, the study’s future is no longer frozen, but it remains surrounded by scrutiny. The revised protocol has been approved, yet the controversy around the original design has already made the trial a test case for how far vaccine research can go when questions about safety, ethics, and geopolitical trust converge on the same study design.